卡瑞利珠单抗联合化疗在EGFR/ALK野生型的晚期非鳞状非小细胞肺癌老年患者中的临床观察
Clinical Observation of Camrelizumab Combined with Chemotherapy in the Elderly with EGFR/ALK Wild-Type,Advanced Non-Squamous Non-Small Cell Lung Cancer
唐一丁 1谭逢艳 2蒙龙 2宋捷 2邱峰 2龙锐2
作者信息
- 1. 重庆医科大学附属第一医院药学部,重庆 400016;四川省中江县人民医院临床药学科,四川 德阳 618100
- 2. 重庆医科大学附属第一医院药学部,重庆 400016
- 折叠
摘要
目的:观察表皮生长因子受体/间变性淋巴瘤激酶(EGFR/ALK)野生型的晚期非鳞状非小细胞肺癌(NSCLC)老年患者接受卡瑞利珠单抗联合化疗的疗效和安全性.方法:选取 2021 年 8 月至 2023 年 2 月重庆医科大学附属第一医院 133 例接受卡瑞利珠单抗联合化疗的EGFR/ALK野生型的晚期非鳞状NSCLC患者,按照年龄分为老年组(≥65 岁)和非老年组(<65 岁),对两组患者的治疗效果和安全性进行回顾性分析.结果:老年组患者的中位无进展生存期长于非老年组(44.14 周 vs.37.71 周),两组患者生存曲线经Log-rank法检验比较,差异无统计学意义(P>0.05).老年组患者的客观缓解率和疾病控制率低于非老年组[客观缓解率:5.33%(4/75)vs.6.90%(4/58);疾病控制率:74.67%(56/75)vs.75.86%(44/58)],但差异均无统计学意义(P>0.05).老年组患者所有级别治疗相关不良事件(TRAE)发生率为 97.33%(73/75),高于非老年组的 84.48%(49/58),差异有统计学意义(P<0.05).老年组和非老年组患者 3 级以上治疗相关不良事件发生率分别为 10.67%(8/75)和 5.17%(3/58),差异无统计学意义(P>0.05).结论:卡瑞利珠单抗联合化疗用于EGFR/ALK野生型的晚期非鳞状NSCLC老年患者的治疗效果与用于非老年患者相当;老年患者的TRAE发生率更高;初步判断老年患者接受治疗时不需要对卡瑞利珠单抗的剂量进行调整.
Abstract
OBJECTIVE:To observe the efficacy and safety of camrelizumab combined with chemotherapy in the elderly with epidermal growth factor receptor/anaplastic lymphoma kinase(EGFR/ALK)wild-type,advanced non-squamous non-small cell lung cancer(NSCLC).METHODS:A total of 133 patients with EGFR/ALK wild-type,advanced non-squamous NSCLC who received camrelizumab combined with chemotherapy in the First Affiliated Hospital of Chongqing Medical University from Aug.2021 to Feb.2023 were extract to be divided into the elderly group(≥65 years old)and non-elderly group(<65 years old)according to patients'age.Therapeutic effect and safety of two groups were analyzed retrospectively.RESULTS:The median progression-free survival in the elderly group was greater than that in the non-elderly group(44.14 weeks vs.37.71 weeks).The survival curves of two groups were tested and compared by Log-rank method,with no statistically significant difference(P>0.05).The objective response rate and disease control rate of the elderly group were lower than those of the non-elderly group[objective response rate:5.33%(4/75)vs.6.90%(4/58);disease control rate:74.67%(56/75)vs.75.86%(44/58)],the difference was not statistically significant(P>0.05).The incidence of treatment-related adverse event(TRAE)in all grades of the elderly group was 97.33%(73/75),which was higher than 84.48%(49/58)of the non-elderly group,with statistically significant difference(P<0.05).The incidence of TRAE above grades 3 in the elderly group and non-elderly group was respectively 10.67%(8/75)and 5.17%(3/58),with no statistically significant difference(P>0.05).CONCLUSIONS:Treatment efficacy were the same in the elderly patients as in non-elderly patients with EGFR/ALK wild-type,advanced non-squamous NSCLC in camrelizumab combined with chemotherapy.Elderly patients have a higher incidence of TRAE;initially,no dose adjustment of camrelizumab is required for the elderly receiving treatment.
关键词
卡瑞利珠单抗/非小细胞肺癌/老年患者/有效性/安全性Key words
Camrelizumab/Non-small cell lung cancer/Elderly patients/Efficacy/Safety引用本文复制引用
基金项目
重庆市医学科研项目(卫生健康委员会和科技局联合)(2023MSXM041)
出版年
2024
国家科技期刊平台
NSTL
万方数据